The Canadian Rheumatology Association strongly recommends that access to citrate-free Humira be made available for Canadian children requiring treatment with Humira.
Business Practice
CME/CE
Subscribe
BIOSIMILAR APPROVALS
- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
In Canada, More Mandatory Switching
In Canada, a new jurisdiction inaugurates mandatory switching to biosimilars.
The Northwest Territories has become the fifth Canadian jurisdiction to mandate switching to biosimilars for patients in the public health system. The Northwest Territories is a sparsely populated (41,000) wilderness area that is known for its native settlements, European immigration, fur trade and gold prospecting history (Yellowknife).
Public officials said in a statement that the biosimilar switching policy will be consistent with those already established in British Columbia, New Brunswick, Alberta, and Quebec. Canada has begun imposing mandatory biosimilar switching programs following lackluster voluntary biosimilar uptake. Biosimilars are highly similar to the original brand drugs they reference and just as safe and efficacious. They enter the market at discounts to the originator drugs and help to bring down the costs of health care and improve patient access to critical medicines.
A statement by Biosimilars Canada, a trade association of biosimilars producers, explained that in the Northwest Territories switching will become mandatory for patients on 10 biologic reference drugs for which biosimilars are available, within the following therapeutic areas: arthritis, diabetes, inflammatory bowel disease, and psoriasis. The transition to biosimilars must occur by June 20, 2022.
“The full benefits of biosimilars cannot be realized unless drug plans adopt policies that support their expanded use with the implementation of successful biosimilar transitioning or “switching” policy,” the group said.
Related Videos
Related Content
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Article
Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024Podcast
On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Article
Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024Podcast
On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Article
Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024Article
The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
